



COVID-19 IMMUNITY
TASK FORCE

Spotlight on CITF-FUNDED RESEARCH



CITF Events



COVID-19
IMMUNITY
TASK FORCE

GRUPE DE TRAVAIL
SUR L'IMMUNITÉ
FACE À LA COVID-19

.....

SEMINAR

The CITF Databank

.....

THURSDAY, DECEMBER 15, 2022
3 P.M. TO 4 P.M. EST

Join our seminar on Thursday

The online seminar will discuss the recently launched **CITF Databank**, which will store archived and harmonized data from over 70 epidemiological and immunological studies of COVID-19 in Canada. The datasets include individual-level responses to standardized questionnaires and SARS-CoV-2 serology and cell-mediated immunity assay results. Canadian and international researchers will discover how they can request access to the

data free of charge to further their projects.

Presentation led by:

DAVID BUCKERIDGE, MD, PhD, FRCPC, Scientific Lead, Data Management & Analysis, CITF; Professor, Department of Epidemiology and Biostatistics, School of Population and Global Health, McGill University

Moderator:

TIMOTHY EVANS, MD, PhD, Executive Director, COVID-19 Immunity Task Force

[Register Now](#)



CITF-Funded Research Results

Infection-acquired seroprevalence nears 70% in October: Canadian Blood Services

Despite 100% of blood donors having vaccine-induced antibodies, infection-acquired seroprevalence continued to rise by the end of October 2022, to 67.3%, up from 63.2% at the end of September. This reflects the continued circulation of Omicron subvariants. Additionally, young donors (17-24 years of age) had the highest seroprevalence (81.7%) compared to all other age groups, despite having high spike antibody concentrations, indicative of prior vaccination. These latest results are from Canadian Blood Services.

[Read more](#)

Few breakthrough infections during the Omicron wave in Ontario

In the *Journal of the Association of Medical Microbiology and Infectious Disease Canada*, researchers with the CITF-funded Safety and Efficacy of Preventative COVID Vaccines (STOPCoV) study reported a low rate of

symptomatic or asymptomatic breakthrough infections (3.4%) of COVID-19 between January 17 and March 29, 2022. All infections were minor in severity.

[Read more](#)

Two doses of COVID-19 vaccines were effective against infections in people living with HIV

A CITF-funded study published in the *International Journal of Infectious Diseases* showed that two doses of COVID-19 vaccine were effective at protecting against SARS-CoV-2 infections in people living with HIV (PLWH) during the pre-Omicron era. While protection was similar to that seen in people without HIV, antibody levels peaked slightly later and waned slightly faster in the PLWH cohort.

[Read more](#)

Most children in a Montreal serosurvey had antibodies against COVID-19

The latest results from the CITF-funded EnCORE study, looking at seroprevalence among children and adolescents in Montreal, found that 58% of kids and teens had infection-acquired antibodies between May and September 2022. Moreover, 38% of the cohort had received a positive COVID-19 diagnosis since January 2022, during the Omicron era. The results, in a report to participants and their parents, are preliminary and have not been peer-reviewed.

[Read more](#)



Share!

Know policymakers or researchers who may be interested in our latest research results? Please share this email and encourage them to subscribe!

[Sign Up](#)

Have a publication we should review or know about? Please share with us at research@covid19immunitytaskforce.ca

Missed an issue of Research Roundup? [View back issues.](#)

The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.